866-997-4948(US-Canada Toll Free)

Acromegaly - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Pharmaceutical

No. of Pages : 80 Pages

Acromegaly - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly Pipeline Review, H1 2017, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 8 and 3 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acromegaly - Overview
Acromegaly - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Acromegaly - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acromegaly - Companies Involved in Therapeutics Development
Aegis Therapeutics LLC
Amryt Pharma plc
Antisense Therapeutics Ltd
Chiasma Inc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Foresee Pharmaceuticals LLC
Glide Pharmaceutical Technologies Ltd
Ionis Pharmaceuticals Inc
Ipsen SA
Italfarmaco SpA
Midatech Pharma Plc
Novartis AG
Peptron Inc
Silence Therapeutics Plc
Strongbridge Biopharma plc
Sun Pharma Advanced Research Company Ltd
Acromegaly - Drug Profiles
Antisense Oligonucleotide to Inhibit Growth Hormone Receptor for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atesidorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIM-23B065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-GHRLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITF-2984 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-779976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate long acting - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somadex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SXN-101959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acromegaly - Dormant Projects
Acromegaly - Discontinued Products
Acromegaly - Product Development Milestones
Featured News & Press Releases
Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
Dec 02, 2016: Amryt Pharma provides update on AP-102
Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly
Sep 22, 2016: Aegis Awarded Patent for Non-Invasive Nasal Octreotide Formulation
Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study
Jul 13, 2016: ATL1103 Patent Update
Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study
Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa
Jun 01, 2016: Antisense provides update on ATL1103 clinical trials
May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI
May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly
Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Acromegaly, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Acromegaly - Pipeline by Aegis Therapeutics LLC, H1 2017
Acromegaly - Pipeline by Amryt Pharma plc, H1 2017
Acromegaly - Pipeline by Antisense Therapeutics Ltd, H1 2017
Acromegaly - Pipeline by Chiasma Inc, H1 2017
Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H1 2017
Acromegaly - Pipeline by DexTech Medical AB, H1 2017
Acromegaly - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Acromegaly - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Acromegaly - Pipeline by Ipsen SA, H1 2017
Acromegaly - Pipeline by Italfarmaco SpA, H1 2017
Acromegaly - Pipeline by Midatech Pharma Plc, H1 2017
Acromegaly - Pipeline by Novartis AG, H1 2017
Acromegaly - Pipeline by Peptron Inc, H1 2017
Acromegaly - Pipeline by Silence Therapeutics Plc, H1 2017
Acromegaly - Pipeline by Strongbridge Biopharma plc, H1 2017
Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Acromegaly - Dormant Projects, H1 2017
Acromegaly - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Acromegaly, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *